Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

New England Journal of Medicine

Volumn 368, Issue 16, 2013, Pages 1509-1518

  Grupp, Stephan A ^a,b   Kalos, Michael ^a,b   Barrett, David ^a   Aplenc, Richard ^a,b   Porter, David L ^a,b   Rheingold, Susan R ^a,b   Teachey, David T ^a,b   Chew, Anne ^a   Hauck, Bernd ^a   Wright, J Fraser ^a   Milone, Michael C ^a,b   Levine, Bruce L ^a,b   June, Carl H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BLINATUMOMAB; CD19 ANTIGEN; CD34 ANTIGEN; CLOFARABINE; CYCLOPHOSPHAMIDE; D DIMER; ETANERCEPT; ETOPOSIDE; FERRITIN; GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 6; LACTATE DEHYDROGENASE; TOCILIZUMAB; URIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT RESPIRATORY DISTRESS SYNDROME; APLASIA; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CLOTTING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CELL EXPANSION; CELL THERAPY; CHILD; CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL; CONFUSION; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE RELEASE SYNDROME; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA SEQUENCE; FEMALE; FEVER; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HEPATOSPLENOMEGALY; HUMAN; HYPOFIBRINOGENEMIA; KARYOTYPE; LEUKEMIA RELAPSE; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; MACROPHAGE ACTIVATION SYNDROME; MYALGIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; T LYMPHOCYTE; TUMOR LYSIS SYNDROME;

EID: 84876325876     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1215134     Document Type: Article

References (26)

1. Barrett AJ, Horowitz MM, Pollock BH, et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med 1994;331:1253-8. (Pubitemid 24333189)
2. Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012;120:2032-41.
3. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-7.
4. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112:2261-71.
5. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099-102.
6. Brentjens RJ, Rivière I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;118:4817-28.
7. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
8. Kalos M, Levine BL, Porter DL, et al. T cells expressing chimeric receptors establish memory and potent antitumor effects in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
9. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011;121:1822-6.
10. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009;17:1453-64.
11. Jensen MC, Popplewell L, Cooper LJ, et al. Anti-transgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010;16:1245-56.
12. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709-20.
13. Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012;119:3940-50.
14. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-50.
15. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-44. (Pubitemid 27074209)
16. Collins RH Jr, Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000;26:511-6.
17. Hotfilder M, Röttgers S, Rosemann A, et al. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. Cancer Res 2005;65:1442-9. (Pubitemid 40270173)
18. le Viseur C, Hotfilder M, Bomken S, et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 2008;14:47-58. (Pubitemid 351885495)
19. Tang Y, Xu X, Song H, et al. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol 2008;143:84-91.
20. Behrens EM, Canna SW, Slade K, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest 2011;121:2264-77.
21. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med 2012;63:233-46.
22. Drobyski WR, Pasquini M, Kovatovic K, et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant 2011;17:1862-8.
23. Tawara I, Koyama M, Liu C, et al. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res 2011;17:77-88.
24. Le Huu D, Matsushita T, Jin G, et al. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. J Invest Dermatol 2012;132:2752-61.
25. Pullen J, Boyett J, Shuster J, et al. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1993;11:839-49. (Pubitemid 23146077)
26. Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001;15:163-205. (Pubitemid 32201872)